Nevertheless, the characterization of the inducers' mechanisms of action has validated the Bcl-2 family members and the Mcl-1/Noxa axis in particular as potential therapeutic targets in CLL. Here, PMAIP1 is linked to B-cell chronic lymphocytic leukemia.